SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (372)1/5/1999 11:32:00 PM
From: Bron-y-aur  Read Replies (2) | Respond to of 1321
 
Ian,

One analyst who has stuck to her guns on this one is Christine Charette from Nesbitt Burns. When the stock was getting trashed, she maintained her target (think it was $45).
Articles in the financial press put her as the #1 biotech analyst in Canada and from what I have seen, she knows and understands the QLT story.
Will try to find out from NB her QLT outlook for 99 and post it.

Sam



To: Ian@SI who wrote (372)1/6/1999 2:23:00 AM
From: Edward W. Richmond  Read Replies (2) | Respond to of 1321
 
Ian, I find Merrill Lynch's(Midland Walwyn) upgrade interesting. This is the company that recommended selling QLT and buying Xillix Technology. When Xillix tanked they discontinued their coverage because of its low market cap.
I take small comfort from ML. Nesbitt is a different matter.
Long on QLT and very happy to be.
Regards, Ed


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News